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HIV-1 drug resistance is an important cause of antiretrovi-
ral failure. Although standard genotypic and phenotypic
tests can detect drug resistance in many cases, both are
limited in their capacity to detect variants present as
minority members of the viral population, particularly at
levels below 5–10%. Recently, several studies have shown
that drug-resistant minority variants present in the popu-
lation prior to initiation of antiretroviral therapy substan-
tially increase the risk of treatment failure. These minority
variants may represent persistence of transmitted drug-
resistant viruses or may represent mutants that have arisen
de novo during the course of infection. Two studies from
our laboratory used different approaches to the detection
of minority variants. In the first study, allele-specific real-
time PCR was used to detect and quantify presence of
minority variants carrying non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) resistance mutations in base-
line plasma samples from subjects enrolled into AIDS
Clinical Trials Group (ACTG) protocol A5095, which
compared the efficacy of three- and four-drug efavirenz-
based regimens. Presence of Y181C mutations even at lev-
els below 1% was associated with a nearly 2.5-fold greater
risk of virological failure. In a second study, ultra-deep
pyrosequencing was used to characterize the diversity of
V3 loop sequences from HIV-1 env present within
infected persons, and to track the dynamic evolution of
the quasispecies in response to treatment with the investi-
gational CCR5 antagonist vicriviroc (VCV). V3 loop forms
associated with subsequent virologic failure, either
through CXCR4 use or the emergence of high-level VCV
resistance, were present as minor variants at 0.8–2.8% of
baseline samples. These studies, along with the work of
other groups, illustrate the clinical significance of minor-
ity drug-resistant populations and the importance of
developing and clinically validating novel technologies
for their detection.
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